Bausch Health Companies Inc
TSX:BHC

Watchlist Manager
Bausch Health Companies Inc Logo
Bausch Health Companies Inc
TSX:BHC
Watchlist
Price: 10.85 CAD 1.12%
Market Cap: 4B CAD
Have any thoughts about
Bausch Health Companies Inc?
Write Note

Gross Margin
Bausch Health Companies Inc

70.9%
Current
71%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.9%
=
Gross Profit
6.7B
/
Revenue
9.5B

Gross Margin Across Competitors

Country CA
Market Cap 4B CAD
Gross Margin
71%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 757B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 350.9B USD
Gross Margin
69%
Country US
Market Cap 252.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.9B USD
Gross Margin
71%
No Stocks Found

Bausch Health Companies Inc
Glance View

Market Cap
4B CAD
Industry
Pharmaceuticals

Bausch Health Companies Inc. stands as a prominent player in the global healthcare arena, with its roots stretching back over a century. Originally known as Valeant Pharmaceuticals, the firm has undergone significant transformation, focusing on a diverse array of health-related products and innovations. The company operates primarily in three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. Each of these divisions articulates its commitment to enhancing patients' lives through high-quality products that address the complex challenges of eye care, gastroenterology, and dermatology, respectively. The Bausch + Lomb sector, named after its foundational company, is recognized globally for its wealth of eye health products, including contact lenses, lens care products, and ophthalmic pharmaceuticals. This sector is integral to Bausch Health's revenue stream, contributing significantly through its diverse portfolio of over-the-counter and prescription offerings. At its core, Bausch Health has honed a business model centered around acquiring and developing specialty pharmaceuticals and health-enhancing technologies. Through strategic acquisitions, partnerships, and internal research, the company curates a vast pipeline of treatments and solutions. Revenue generation for Bausch Health is intrinsically linked to its global market footprint, operating in more than 100 countries. Sales teams across these regions work diligently to ensure that healthcare professionals and consumers alike have access to their products. Meanwhile, the company's commitment to innovation helps it remain responsive in rapidly evolving medical fields. The sales and marketing strategies are finely tuned to address regional disparities, leveraging local insights to maximize market penetration and bolster growth. Ultimately, Bausch Health Companies Inc. thrives by bridging high-quality health solutions with unmet global needs, seeking to leave a lasting impact on the lives it touches.

BHC Intrinsic Value
118.99 CAD
Undervaluation 91%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
70.9%
=
Gross Profit
6.7B
/
Revenue
9.5B
What is the Gross Margin of Bausch Health Companies Inc?

Based on Bausch Health Companies Inc's most recent financial statements, the company has Gross Margin of 70.9%.